The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
The purpose of this study is to compare how the study drug ARN-509, when used alone or in combination with a commonly used medicine called a Luteinizing Hormone-Releasing Hormone (LHRH) agonist, affects your quality of life, your overall health, and your prostate cancer after 12 months of treatment.
Biochemically Relapsed Hormone Sensitive Prostate Cancer
-Rising PSA after prior definitive therapy for localized prostate cancer, including radical prostatectomy, external beam radiation therapy, brachytherapy, or combination of radical prostatectomy and radiotherapy.
-Minimum PSA of 1.0ng/mL (prostatectomy) or 2.0 ng/mL (without prostatectomy).
-No evidence of metastatic disease.
-Does not have a history of osteoporosis.
-Does not have a history of seizures or medical condition which lowers seizure threshold.
18 - 100
Healthy Volunteers Needed
Duration of Participation
12 months on active treatment, 12 months of follow-up
Clinical trials information line: Phone 503-494-1080 or email@example.com